DEFA14A: ABVC BioPharma Seeks Stockholder Approval for Increased Share Issuance Related to Lind Global Funding

ABVC BioPharma is seeking stockholder approval to issue shares related to convertible notes and warrants issued to Lind Global Fund II, LP, to comply with Nasdaq listing rules, as part of a financing transaction to address the company's cash needs.

Summary

• ABVC BioPharma is seeking stockholder approval for a proposal to authorize the issuance of shares of common stock underlying convertible notes and warrants issued to Lind Global Fund II, LP.
• The company entered into securities purchase agreements with Lind in November 2023 and January 2024, issuing convertible notes and warrants to raise capital.
• The initial Annual Meeting was adjourned due to a lack of quorum and is rescheduled for April 16, 2024.
• The company is seeking approval to issue more than 20% of its outstanding shares of common stock to Lind, if necessary, due to anti-dilution provisions in the agreements.
• The Board of Directors approved an amendment to the company's bylaws that reduced the quorum for shareholder meetings from a majority to 33 1/3% of the outstanding voting securities.
• As of the Record Date, March 8, 2024, there were 10,560,421 shares of Common Stock outstanding and entitled to vote.
• The company's cash and cash equivalents as of December 31, 2023, were approximately $60,155.
• The Lind Offerings yielded gross proceeds of $2.2 million.
• The company is required to seek shareholder approval on or before April 17, 2024, and every four months thereafter until approval is obtained.
• The Board unanimously recommends that stockholders vote FOR the Issuance Proposal.

Sentiment

Score: 5

Explanation: The document highlights both the need for financing and the potential dilution to shareholders. The company is taking necessary steps to comply with regulations, but the overall sentiment is neutral due to the inherent risks and benefits of the financing transaction.

Positives

• The Lind Offerings provided necessary funding for general corporate purposes when the company had limited cash reserves.
• The Board considered numerous alternatives and determined that the Lind Offerings were the most feasible and favorable option at the time.
• The company is taking steps to comply with Nasdaq listing rules by seeking stockholder approval for the share issuance.
• The amendment to the company's bylaws reduces the quorum requirement, potentially making it easier to conduct shareholder meetings.

Negatives

• The company's cash and cash equivalents were very low as of December 31, 2023, indicating a need for immediate funding.
• The potential issuance of a significant number of shares to Lind could dilute the ownership of existing stockholders.
• Failure to obtain stockholder approval could result in an Event of Default under the Lind Notes, requiring the company to pay Lind 120% of the outstanding principal amount.
• The Lind Notes and Warrants contain anti-dilution provisions that could lead to the issuance of more shares than initially anticipated.

Risks

• Failure to obtain stockholder approval for the share issuance could trigger an Event of Default under the Lind Notes.
• The potential issuance of a significant number of shares to Lind could dilute the ownership of existing stockholders and decrease the value of their shares.
• The anti-dilution provisions in the Lind Notes and Warrants could result in the issuance of more shares than initially anticipated, further diluting existing stockholders.
• The increased number of issued shares may have an incidental anti-takeover effect, potentially discouraging or making more difficult certain mergers, tender offers, proxy contests or other change of control or ownership transactions.

Future Outlook

The company intends to continue seeking stockholder approval for the share issuance until it is obtained, and will hold meetings every four months if necessary.

Management Comments

• The Board determined that it was necessary to raise additional funds for general corporate purposes.
• The Board considered numerous alternatives to the transaction, none of which proved to be feasible or, in the opinion of our Board, would have resulted in aggregate terms equivalent to, or more favorable than, the terms obtained in the Lind Offerings.

Industry Context

Many small biopharmaceutical companies rely on private placements and convertible debt financing to fund operations, especially during early stages of development. These financings often include provisions that can lead to significant dilution for existing shareholders.

Comparison to Industry Standards

• Convertible notes and warrants with anti-dilution provisions are common in financings for small-cap biotech companies.
• The specific terms of the Lind Offerings, including the conversion price, warrant exercise price, and anti-dilution adjustments, would need to be compared to similar transactions in the biotech industry to assess their favorability.
• Companies like Athersys and Ocugen have used similar financing structures to raise capital, but the terms vary widely based on the company's stage of development, market conditions, and investor appetite.

Corporate Governance

Stakeholder Impact

• Shareholders may experience dilution of their ownership if the share issuance is approved.
• The company's ability to continue operations and pursue its business strategy depends on securing the necessary funding.
• Failure to obtain stockholder approval could negatively impact the company's financial condition and its ability to meet its obligations.

Next Steps

• Stockholders must vote on the proposals being considered at the Annual Meeting by one of the alternatives described in the Proxy Statement.
• The company will hold the Annual Meeting on April 16, 2024, to vote on the proposals.
• The company may need to call additional meetings every four months to seek shareholder approval if it is not obtained at the Annual Meeting.

Key Dates

Keywords

ABVC BioPharma, Lind Global Fund II, share issuance, convertible notes, warrants, stockholder approval, Nasdaq Listing Rule 5635(d), anti-dilution, financing, quorum